Sweden-based clinical-stage medical company Pulmologix has secured €9.6m ($12m) in a series B round led by Novo Seeds, the seed fund of pharmaceutical company Novo.
Venture capital firms Sunstone Capital, Forbion Capital Partners and HealthCap were also involved. The funding will be used to develop an oral non-steroidal treatment for early onset allergic asthma.
Following the round, Bobby Soni, investment director of Novo Seeds, and Andreas Segerros of Sunstone have joined Pulmologix’ board of sirectors.